Eurofarma reinforces its presence in Chile with the acquisition of Medipharm
With this acquisition, the company takes the 21st position in the Chilean market and becomes the 4th largest regional-owned pharmaceutical company in the country.
The acquisition will provide a significant growth to its operations and is aligned with the objectives defined in its strategic plan – 2022 vision, which establishes that its international operations should account, within that timeframe, for 30% of the company´s revenues, as explained by Mrs. Maria del Pilar Muñoz, Vice-President of Sustainability and New Businesses. "Medipharm has been in the market since 1985 and has done an intense work at points of sale and to build their brands. With this acquisition, our total international sales should increase by up to 10% and, specifically in Chile, we should be among the 4 largest Latin-American-
For Empresas SB, their motivation to sell Medipharm has been related to their bet on the company´s "core business." "We´ve decided to focus on our main activity, retail business and the management of our network of drugstores. This transaction goes along the company´s strategic decision to concentrate our efforts and investments in drug sale and distribution,"
The pharmacy channel in Chile generated audited sales amounting to US$ 1.73 billion in 2018, a 4.4% growth over the previous year, and the country answers or 5.3% of sales in the region. Medipharm has a portfolio with more than 140 medicines, including neurological, respiratory and gastrointestinal drugs, thus aggregating higher value to Eurofarma´s portfolio, which counts on more than 100 products available in the Chilean territory. "The acquisition of that company will enable us to increase our revenues from Eurofarma Chile by 75%. In addition to that, we have acquired a state-of-the-
About the Eurofarma Group
Eurofarma is a health company dedicated to offering products and services to improve people´s lives with quality, innovation, and at fair prices in all main pharmaceutical segments: Medical Prescription, Non-Prescription Medicines, Generic Drugs, Hospital Inputs, Oncology and Veterinarian Products. In Brazil alone, the company offers 287 different molecules and more than 600 products. As a leader in the medical prescription sector, it tends to 30 different specialties and covers 101 therapeutic classes, which account for 89% of sales in the pharmaceutic retail segment. It has the largest sales force in the country, and every month undertakes approximately 600 thousand medical contacts.
Founded in 1972, and as the first 100% Brazilian-owned pharmaceutical multinational company, it has operations in 20 countries, in addition to an important industrial park in Brazil and plants in 6 other countries in Latin America. In 2018, the group generated sales amounting to R$ 4.3 billion, and it employs more than 6.7 thousand collaborators.
About SB Companies
SB Companies is a holding dedicated to deliver a wide range of products and services involving health and beauty, comprising ten subsidiaries, and counting on approximately 10,000 collaborators and over 600 points of sale across the country.
More infomation: https://www.eurofarma.com.br/